Avacta Group Plc (AVCTF) Discusses Initial Faridoxorubicin Phase Ib Data and Safety Profile in Salivary Gland Cancer Transcript
Source: SeekingAlpha
2025-12-17 15:29:18 ET
Avacta Group Plc (AVCTF) Discusses Initial Faridoxorubicin Phase Ib Data and Safety Profile in Salivary Gland Cancer December 17, 2025 5:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Avacta Group Plc (AVCTF) Discusses Initial Faridoxorubicin Phase Ib Data and Safety Profile in Salivary Gland Cancer Transcript
Avacta Group Plc
NASDAQ: AVCTF
AVCTF Trading
0.01% G/L:
$0.8248 Last:
2,900 Volume:
$0.82475 Open:
AVCTF Latest News
February 24, 2026 02:00:00 am
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
February 03, 2026 07:00:00 am
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
AVCTF Stock Data
$367,242,821
350,422,643
82.5%
39
N/A
Biotechnology & Life Sciences
Healthcare
GB
Wetherby
